It's hardly surprising that one of the Australian biotechnology industry's biggest bugbears is a communication gap between companies and their investors.

South Australian genomics company Bionomics (ASX:BNO) has received a notice of allowance for a US patent, forming part of the company's patent portfolio covering a diagnostic test for severe forms of childhood epilepsy.

Brisbane biopharma Alchemia's (ASX:ACL) financial results for the year ending June 3 reveal that the firm has $15.9 million in the bank to support the development program of its lead anti-cancer drug candidate ACL 16907.

Researchers at the Walter and Eliza Hall Medical Research Australian and the University of California have developed one of the hottest prospective drug therapies for the paralysing neurodegenerative disorder multiple sclerosis (MS).

There's no tyranny in distance for some globetrotting Australian biotechnology companies, writes Michael Vitale

South Australian genomics company Bionomics (ASX:BNO) has found that antibodies against it's proprietary cancer drug target BNO69 can be used to distinguish between malignant and benign breast cancers.

Thebarton (SA) epilepsy specialist Bionomics (ASX:BNO, BNOOA; US OTC:BMICY) is getting positive feedback on its newly commercialised DNA diagnostic for severe myoclonic epilepsy of infancy (SMEI).

Four new members have been appointed to the Australian Biotechnology Advisory Council (ABAC) -- the independent board of industry experts advising the government on biotech issues.

The dark clouds over venerable Adelaide biopharma BresaGen (ASX:BGN) have parted, revealing a little blue sky. But the resurrected company's business plan is focused on terra firma -- it is going back to its roots as a service company.

Bionomics (ASX:BNO) has acquired unlisted Melbourne discovery company Iliad Chemicals for 40.9 million Bionomics shares - approximately AUD$6.1 million at current market prices.

Melbourne-based biotech Prima Biomed (ASX:PRR) has been granted a patent by the European Patent Office for its CancerVac therapy, and nanotechnology company pSivida (ASX:PSD, NASDAQ:PSDV, Xetra:PSI) has been granted its first Chinese patent.